ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 560,50
-0,95%
Dow Jones
40 640,05
1,07%
DAX
18 470,66
-0,70%
Brent Oil
83,105
-1,46%
Bitcoin
63 462,35
-2,14%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
09/08/202322h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SMMTSummit Therapeutics Inc
09/08/202314h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
09/08/202313h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023NASDAQ:SMMTSummit Therapeutics Inc
02/08/202314h00Business WireSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023NASDAQ:SMMTSummit Therapeutics Inc
05/06/202314h44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SMMTSummit Therapeutics Inc
04/06/202314h00Business WirePromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023NASDAQ:SMMTSummit Therapeutics Inc
01/06/202313h30Business WireIvonescimab Updated Data to be Featured at ASCO 2023NASDAQ:SMMTSummit Therapeutics Inc
11/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SMMTSummit Therapeutics Inc
11/05/202313h30Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
09/05/202313h30Business WireSummit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)NASDAQ:SMMTSummit Therapeutics Inc
03/05/202314h30Business WireSummit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)NASDAQ:SMMTSummit Therapeutics Inc
28/04/202312h20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
21/04/202317h02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SMMTSummit Therapeutics Inc
17/03/202321h26Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SMMTSummit Therapeutics Inc
13/03/202321h53Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
09/03/202322h56Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SMMTSummit Therapeutics Inc
09/03/202313h30Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022NASDAQ:SMMTSummit Therapeutics Inc
08/03/202323h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SMMTSummit Therapeutics Inc
08/03/202322h59Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:SMMTSummit Therapeutics Inc
03/03/202314h00Business WireSummit Therapeutics Closes Fully-Subscribed $500 Million Rights OfferingNASDAQ:SMMTSummit Therapeutics Inc
23/02/202314h00Business WireSummit Therapeutics’ Rights Offering Nearing Expiration DateNASDAQ:SMMTSummit Therapeutics Inc
07/02/202313h01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:SMMTSummit Therapeutics Inc
30/01/202314h00Business WireSummit Therapeutics Announces Timing for Rights Offering for Up to $500 MillionNASDAQ:SMMTSummit Therapeutics Inc
26/01/202320h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SMMTSummit Therapeutics Inc
23/01/202312h04Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SMMTSummit Therapeutics Inc
20/01/202314h00Business WireSummit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific AntibodyNASDAQ:SMMTSummit Therapeutics Inc
05/01/202313h00Business WireSummit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
06/12/202222h46TipRanksSummit Therapeutics Explodes Up on Licensing DealNASDAQ:SMMTSummit Therapeutics Inc
06/12/202213h30GlobeNewswire Inc.Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific AntibodyNASDAQ:SMMTSummit Therapeutics Inc
17/11/202222h15GlobeNewswire Inc.Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

LSE
0LME
Vanguard Developed Marke...
COIN
MINAUSD
Mina
LSE
LWI
Lowland Investment
LSE
EXO
Exova
NYSE
TYL
Tyler Technologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés